NZ760008A - Uti fusion proteins - Google Patents

Uti fusion proteins

Info

Publication number
NZ760008A
NZ760008A NZ760008A NZ76000815A NZ760008A NZ 760008 A NZ760008 A NZ 760008A NZ 760008 A NZ760008 A NZ 760008A NZ 76000815 A NZ76000815 A NZ 76000815A NZ 760008 A NZ760008 A NZ 760008A
Authority
NZ
New Zealand
Prior art keywords
fusion proteins
amino acids
uti
protein
uti fusion
Prior art date
Application number
NZ760008A
Other languages
English (en)
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Original Assignee
Takeda Pharmaceuticals Co
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Takeda Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of NZ760008A publication Critical patent/NZ760008A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • C07K14/8117Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/90Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
NZ760008A 2014-02-24 2015-02-23 Uti fusion proteins NZ760008A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
NZ724196A NZ724196A (en) 2014-02-24 2015-02-23 Uti fusion proteins

Publications (1)

Publication Number Publication Date
NZ760008A true NZ760008A (en) 2023-03-31

Family

ID=52629709

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ760008A NZ760008A (en) 2014-02-24 2015-02-23 Uti fusion proteins
NZ724196A NZ724196A (en) 2014-02-24 2015-02-23 Uti fusion proteins
NZ760789A NZ760789A (en) 2014-02-24 2015-02-23 Uti fusion proteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ724196A NZ724196A (en) 2014-02-24 2015-02-23 Uti fusion proteins
NZ760789A NZ760789A (en) 2014-02-24 2015-02-23 Uti fusion proteins

Country Status (38)

Country Link
US (4) US9856310B2 (enExample)
EP (2) EP3110434B1 (enExample)
JP (4) JP6574431B2 (enExample)
KR (3) KR20240155987A (enExample)
CN (2) CN106232135B (enExample)
AR (1) AR101597A1 (enExample)
AU (4) AU2015218704B2 (enExample)
BR (1) BR112016019390B1 (enExample)
CA (2) CA2939639C (enExample)
CL (1) CL2016002136A1 (enExample)
CR (1) CR20160444A (enExample)
CY (1) CY1120997T1 (enExample)
DK (1) DK3110434T3 (enExample)
DO (1) DOP2016000202A (enExample)
EA (2) EA037256B1 (enExample)
EC (1) ECSP16076535A (enExample)
ES (1) ES2700149T3 (enExample)
GE (1) GEP20196970B (enExample)
HR (1) HRP20182029T1 (enExample)
IL (1) IL247321B (enExample)
JO (1) JO3729B1 (enExample)
LT (1) LT3110434T (enExample)
MA (1) MA39347B2 (enExample)
MX (4) MX384070B (enExample)
MY (1) MY178774A (enExample)
NZ (3) NZ760008A (enExample)
PE (1) PE20170257A1 (enExample)
PH (1) PH12016501629B1 (enExample)
PL (1) PL3110434T3 (enExample)
PT (1) PT3110434T (enExample)
RS (1) RS58285B1 (enExample)
SG (2) SG11201606691QA (enExample)
SI (1) SI3110434T1 (enExample)
SM (1) SMT201800674T1 (enExample)
TW (1) TWI694084B (enExample)
UA (1) UA118866C2 (enExample)
WO (1) WO2015127391A1 (enExample)
ZA (1) ZA201606327B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3110434T (lt) * 2014-02-24 2018-12-27 Takeda Gmbh Sulieti uti baltymai
BR112019025792A2 (pt) 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
EP4114428A4 (en) * 2020-03-05 2025-03-12 Diamedica USA Inc. ULINASTATIN POLYPEPTIDES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE59007737D1 (de) * 1989-05-13 1995-01-05 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.
JPH0584083A (ja) 1990-11-13 1993-04-06 Mochida Pharmaceut Co Ltd 新規ポリペプチド、それをコードする新規dna、新規ポリペプチドの製造方法、新規医薬組成物、および新規酵素阻害方法
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
DK0891426T3 (da) 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
WO2005095457A2 (en) * 2004-03-30 2005-10-13 Glaxo Group Limited Immunoglobulins
CA2578613A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
EP1889908A4 (en) * 2005-06-03 2012-04-25 Mochida Pharm Co Ltd PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
LT1981519T (lt) 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
PL2536745T3 (pl) * 2010-02-19 2017-01-31 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
JP6063450B2 (ja) * 2011-04-29 2017-01-18 ユニヴァーシティ オブ ワシントン 治療用ヌクレアーゼ組成物および方法
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
CN110078831A (zh) * 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
WO2013162050A1 (ja) * 2012-04-23 2013-10-31 株式会社Nrlファーマ ラクトフェリン融合タンパク質及びその製造方法
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华(上海)生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのFc融合タンパク質並びにその調製および使用
LT3110434T (lt) * 2014-02-24 2018-12-27 Takeda Gmbh Sulieti uti baltymai

Also Published As

Publication number Publication date
ES2700149T3 (es) 2019-02-14
UA118866C2 (uk) 2019-03-25
CA2939639A1 (en) 2015-08-27
US20160362475A1 (en) 2016-12-15
EA037256B1 (ru) 2021-02-26
MX384070B (es) 2025-03-14
EP3110434B1 (en) 2018-09-19
EA202091567A1 (ru) 2021-07-30
CA3178241A1 (en) 2015-08-27
KR102461210B1 (ko) 2022-10-31
EA201691702A1 (ru) 2017-01-30
US10351618B2 (en) 2019-07-16
TWI694084B (zh) 2020-05-21
US20200040062A1 (en) 2020-02-06
JO3729B1 (ar) 2021-01-31
PE20170257A1 (es) 2017-03-30
WO2015127391A1 (en) 2015-08-27
BR112016019390B1 (pt) 2023-11-14
AU2021225156A1 (en) 2021-09-30
CN106232135A (zh) 2016-12-14
JP2017512058A (ja) 2017-05-18
JP6938565B2 (ja) 2021-09-22
HRP20182029T1 (hr) 2019-02-08
MX2019013124A (es) 2020-08-31
CN106232135B (zh) 2019-12-10
DOP2016000202A (es) 2016-12-15
JP2023123763A (ja) 2023-09-05
ZA201606327B (en) 2019-01-30
NZ760789A (en) 2023-03-31
MA39347A1 (fr) 2018-06-29
PH12016501629B1 (en) 2023-10-20
US9856310B2 (en) 2018-01-02
MA39347B2 (fr) 2020-05-29
US20180072795A1 (en) 2018-03-15
AR101597A1 (es) 2016-12-28
JP6574431B2 (ja) 2019-09-11
CA2939639C (en) 2023-01-24
SMT201800674T1 (it) 2019-01-11
AU2023200875A1 (en) 2023-04-27
SG10201708400QA (en) 2017-11-29
US20220127334A1 (en) 2022-04-28
CN110092837B (zh) 2024-01-02
CL2016002136A1 (es) 2017-08-11
MX2024000004A (es) 2024-02-20
KR20240155987A (ko) 2024-10-29
AU2019204448A1 (en) 2019-07-11
AU2015218704B2 (en) 2019-05-02
PT3110434T (pt) 2018-12-19
AU2015218704A1 (en) 2016-09-22
KR20160141718A (ko) 2016-12-09
MX2016010950A (es) 2017-04-25
JP2019187427A (ja) 2019-10-31
KR20220151005A (ko) 2022-11-11
MY178774A (en) 2020-10-20
NZ724196A (en) 2022-01-28
DK3110434T3 (en) 2019-01-14
CR20160444A (es) 2017-04-21
PH12016501629A1 (en) 2017-02-06
CN110092837A (zh) 2019-08-06
JP2022002513A (ja) 2022-01-11
PL3110434T3 (pl) 2019-01-31
KR102722304B1 (ko) 2024-10-28
SG11201606691QA (en) 2016-09-29
BR112016019390A2 (pt) 2017-10-24
LT3110434T (lt) 2018-12-27
SI3110434T1 (sl) 2019-02-28
GEP20196970B (en) 2019-04-25
EP3443978A1 (en) 2019-02-20
TW201630931A (zh) 2016-09-01
IL247321B (en) 2020-06-30
CY1120997T1 (el) 2019-12-11
EP3110434A1 (en) 2017-01-04
RS58285B1 (sr) 2019-03-29
IL247321A0 (en) 2016-09-29
ECSP16076535A (es) 2017-08-31
AU2019204448B2 (en) 2021-06-10
AU2021225156B2 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
NZ760008A (en) Uti fusion proteins
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
MX2021015182A (es) Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso.
PH12019502847A1 (en) Novel t cell receptors and immune therapy using the same
MX348071B (es) Variantes de fc.
NZ748307A (en) Gdf15 fusion proteins and uses thereof
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2014004359A (es) Proteina naglu humana recombinante y usos de la misma.
MX2020005127A (es) Plataforma de presentacion en endosporas basadas en paenibacillus, productos y metodos relacionados.
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
HRP20190970T1 (hr) Polipeptidi koji sadrže neglikozilirani fc
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EA201790976A1 (ru) Терапевтические вакцины против hpv16
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX2017005467A (es) Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
MX365560B (es) Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes.
GB2543713A (en) Polymeric proteins and uses thereof
NZ707615A (en) Novel immunotherapeutic molecules and uses thereof
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 FEB 2025 BY AJ PARK

Effective date: 20240214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 FEB 2026 BY AJ PARK

Effective date: 20241224